Medexprim and Deeplink Medical join forces to combine retrospective and prospective data analysis to accelerate clinical oncology research involving medical imaging.  

Medexprim, the European leader in enriched multi-omics and muticentric datasets aggregating clinical, genomic and imaging data, promotes collaboration between centers, public actors and industry to make clinical studies more efficient. Medexprim offers a catalog of European datasets dedicated to lung, kidney, liver, breast and prostate cancers, based on its expertise in quality control, enrichment and anonymization of data, including imaging. 

As an expert in centralized evaluation and review of medical images, Deeplink Medical offers platforms and services to optimize and accelerate the care process. MIRIO, a workflow platform, supports healthcare professionals in the fight against cancer for oncology monitoring and evaluation of solid tumors in routine and clinical trials. 

By combining their expertise, Medexprim and Deeplink Medical offer clinical research actors the possibility to base their studies on the combined analysis of retrospective and prospective data, with converging interests. 

Integrating retrospective data from the very beginning of a study allows better calibration of the criteria for evaluating the effectiveness of new products brought to market. The analysis of retrospective data also allows to refine the answer to clinical questions and to evaluate current practices in the indications of interest with greater precision.

The combination of retrospective and prospective data in the design and monitoring of clinical studies will make it possible to respond to the significant demand of the global market, reduce the costs and delays of clinical trials, while enhancing the excellence of French and European university hospitals and cancer centers.
French version of the PR

About Deeplink Medical
Based in Lyon and founded in 2014, Deeplink Medical digitalizes medical imaging by offering platforms to optimize and accelerate care paths. At the initiative of 5 radiologists, Deeplink Medical builds its solutions around the patient, based on the latest technological and medical innovations, and according to the best practices of the sector (ISO 27001 and HDS certifications, CE marking “medical device”). Today, some fifty employees are working in our three areas of excellence: medical, R&D, and operations, to ensure the ongoing development of our platforms. More than 130 health establishments in France trust us and have chosen ITIS for the management of radiological and remote radiological examinations, MIRIO for oncological monitoring and evaluation of therapeutic response and our DICOM image transfer solution: the DLMbox.

More information is available at: deeplink-medical.com
Press contact: Sarah THOMAS – communication@deeplink-medical.com   

About Medexprim
REAL-WORLD EVIDENCE FOR BETTER CARE
Medexprim is the European leader in secure imaging and clinical data extraction to accelerate medical research. As a Real-World data specialist, Medexprim builds bridges between European academic hospitals, and pharmaceutical, AI and medical device companies. In compliance with the GDPR, Medexprim helps hospitals boost their clinical research strategy and valorize their data, through a suite of software and services designed with and for clinicians. Medexprim provides its partners with secure access to complex, regulatory-grade, multi-omics and multicentric datasets to serve oncology, neurology and cardiology, and help solve the “one patient, one disease, one treatment” equation to accelerate personalized medicine.

Medexprim Linkedin
Medexprim Press contact: Anne-Sophie Labeta – aslabeta@medexprim.com